Senti Biosciences (NASDAQ:SNTI – Get Free Report) and Ginkgo Bioworks (NYSE:DNA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
Earnings and Valuation
This table compares Senti Biosciences and Ginkgo Bioworks”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $2.56 million | 8.46 | -$71.06 million | ($15.56) | -0.30 |
| Ginkgo Bioworks | $251.46 million | 2.92 | -$892.87 million | ($13.08) | -0.98 |
Senti Biosciences has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 0 | 0 | 1 | 0 | 3.00 |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
Senti Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 111.86%. Ginkgo Bioworks has a consensus price target of $4.58, suggesting a potential downside of 64.15%. Given Senti Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Ginkgo Bioworks.
Profitability
This table compares Senti Biosciences and Ginkgo Bioworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -154.84% | -77.42% |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
Institutional & Insider Ownership
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 15.9% of Senti Biosciences shares are held by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Senti Biosciences has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Summary
Senti Biosciences beats Ginkgo Bioworks on 8 of the 13 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
